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Abstract 
Regulation of cancer-specific miRNAs by MDA-7/IL-24 
By Danielle Scheunemann, B.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at 
Virginia Commonwealth University, 2019. 
 
Advisor: Paul B. Fisher, M.Ph., Ph.D. 
Professor and Chair, Department of Human and Molecular Genetics 
Director, VCU Institute of Molecular Medicine 
Thelma Newmeyer Corman Chair in Cancer Research, VCU Massey Cancer Center 
 
Melanoma differentiation associated gene 7/Interleukin-24 (MDA-7/IL-24) is a secreted cytokine which 
acts as a tumor suppressor. It is capable of selectively killing cancer cells, regardless of anatomic origin, 
while sparing normal cells. miRNAs are master regulators of gene expression that can play two roles in 
cancer: tumor-suppression and oncogenesis. We identified a number of miRNAs that are regulated by 
MDA-7/IL-24 using a PCR plate array containing probes for miRNAs known to play a role in prostate 
cancer. We independently validated the array with qRT-PCR to identify three miRNAs which are 
downregulated by MDA-7/IL-24 treatment in DU145, PC3, and PC3ML prostate cancer lines. These 
miRNAs were miR-125a, miR-145, and miR-23b. Their gene targets were identified using TargetScan and 
confirmed to be regulated in our prostate cancer model. NLRC5, KLF4, and KLF15, respectively, were 
upregulated after treatment with MDA-7/IL-24. We focused on NLRC5 as a novel target of MDA-7/IL-24, 
which plays a role in immune evasion by cancer cells. NLRC5 is upregulated following inhibition of miR-
125a. It is not downregulated by overexpression of miR-125a which suggests that more than one miRNA 
may be acting to regulate its expression. Finally, we determined that miR-125a is downregulated by 
MDA-7 through DICER, an important processing enzyme for miRNA biogenesis.
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Introduction 
Prostate Cancer 
 Prostate cancer is the most common cancer among men in industrialized parts of the 
world including North America, Western and Northern Europe, and Australia. Incidence varies 
with ethnicity and geography, but the risk increases with age. In the early stages, the cancer is 
localized and the 5-year survival rate with early detection is almost 100%. When tumors 
metastasize, often to bone, and become metastatic castration-resistant prostate cancer 
(mCRPC), the disease becomes high risk and lethal for most men1,2.  
 The occurrence of prostate cancer is first evident at about age 45 in men. The mean age 
of diagnosis is 67 with 35.3% of diagnoses being in men from age 65 to 742.  African American 
men are affected at the highest rate and have the highest mortality rate as well. East, 
Southeast, and South-Central Asian men have the lowest rate of incidence and lowest mortality 
rate. Prostate cancer is heritable, but identifying genes which contribute to disease progression 
has proven difficult3. HPC14,5, PCAP5, HPCX4, CAPB6, HPC207, and HOXB138 have been identified 
in European populations and validated in other ethnicities1 . However, these genes are not 
included in genetic testing as their risk and the effect of treatment have not been determined. 
However, mutations in BRCA2 can be detected through genetic testing and have been found to 
be associated with aggressive prostate cancer9. Age, ethnicity, and genetic predisposition all 
play a role in the development of prostate cancer, but, as with many cancers, environmental 
factors such as diet and smoking also play a role1,2.   
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 Prostate cancer can be diagnosed with a digital rectal examination, trans-rectal 
ultrasound, and serum prostate-specific antigen with a confirmation by biopsy2. Currently, 
treatment options include prostatectomy for the local tumor, and radiotherapy with or without 
androgen-deprivation therapy (ADT) for high-risk tumors and metastasis. ADT inhibits the 
binding of testosterone with the androgen receptors in order to inhibit cellular proliferation10. 
Prior to 2004, chemotherapy only provided a palliative effect with no increase in survival. It is at 
this point that docetaxel, a new chemotherapeutic, came on the scene. Treatment with 
docetaxel increased patient survival and improved quality of life. It became the standard for 
treatment of metastatic castration-resistant prostate cancer11. Combining chemotherapy with 
ADT has led to a greater improvement of patient outcomes, but the question became how long 
to continue the ADT. Long-term treatment up to 3 years improved disease-free survival12. 
However, some physicians feel differences between short-term and long-term treatment are 
not significant. Long-term ADT also comes with side effects such as hot flushes, insomnia, 
decreased sexual interest, anemia, development of insulin resistance, and bone density 
loss13,14,  thus, leaving the field without a consensus on the best length of treatment with ADT.  
Although there is a standard course of treatment for prostate cancer, 10-20% of 
patients develop resistance to treatment15. New strategies for the detection and treatment of 
mCRPC are coming into the field in order to minimize side effects and increase efficiency of 
treatment. Many researchers are taking advantage of the prostate-specific membrane antigen 
(PSMA) for targeted therapy. PSMA is overexpressed on prostate cancer cells making it an ideal 
marker for targeted therapies. Clinical trials using radiolabeled anti-PSMA antibody such as J591 
demonstrated improved targeting of prostate cancer16. Many radiolabeled drugs using a PSMA 
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ligand for targeting have been developed. Many of them have been used for diagnosis and non-
invasive imaging through positron emission tomography (PET) or single photon emission 
computed tomography (SPECT). Combining the PSMA ligand with a radiotherapy agent or small 
molecule inhibitor enables direct targeted treatment as PSMA is internalized by endocytosis 
leading to enhanced uptake and retention of a drug in the cancer cells17,18.  
MDA-7/IL-24 
 Melanoma differentiation associated gene-7 (MDA-7) which is also known as 
interleukin-24 (IL-24) is a secreted cytokine and a member of the interleukin 10 (IL-10) gene 
family which plays an anti-cancer role in a wide range of cancers4,19. The initial designation of 
mda-7 emanates from the discovery of this gene through subtraction hybridization of cDNA 
libraries from melanoma cells induced to terminally differentiate. MDA-7/IL-24 was found to be 
upregulated in melanoma cells that were terminally differentiating20,21,22. The Human Gene 
Organization named it IL-24 because it shares a chromosomal region with IL-10 genes as well as 
containing an IL-10 signature sequence23.  
 The mda-7/IL-24 gene contains seven exons and six introns which encodes a 206-amino 
acid protein23. At the N-terminus, there is a 49-amino acid hydrophobic signal peptide that is 
cleaved to enable protein secretion. MDA-7/IL-24 can be glycosylated at three amino acids: 85, 
99, and 126. The IL-10 signature sequence is at amino acids 101 and 121. In addition, there are 
three protein kinase C consensus phosphorylation sites and three casein kinase II consensus 
phosphorylation sites. MDA-7/IL-24 functions through its receptors: IL-20R1/IL-20R2, IL-
22R1/IL-20R2, or IL-22R1/IL-20R124. MDA-7/IL-24 is then internalized and localizes to the 
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endoplasmic reticulum (ER) where it induces an ER stress response in a cancer-selective 
manner25,26,27. MDA-7/IL-24 protein can be secreted from cells after cleavage and then induce 
MDA-7/IL-24 expression in surrounding cells28. This bystander effect is how MDA-7/IL-14 
induces apoptosis in distant cancer cells25,29.  
 MDA-7/IL-24 is expressed in immune cells and melanocytes and can be expressed in 
keratinocytes after immune stimulation. It plays a role in proinflammatory, infectious, 
autoimmune diseases, but the function that is most pertinent to this work is the cancer-specific 
killing30. One hallmark of cancer is resistance to cell death. Cancer cells can accomplish this 
through avoidance of apoptotic pathways31,32 and increasing protective autophagy33,34,35.  MDA-
7/IL-24 overcomes this hurdle by inducing ER stress and mitochondrial apoptotic pathways 
through the production of reactive oxygen species (ROS). MDA-7/IL-24 induces expression of 
pro-apoptotic proteins such as PUMA, Bim, Bax, and Bak while inhibiting anti-apoptotic 
proteins such as BCL-2. MDA-7/IL-24 tips the scale from protective autophagy to toxic 
autophagy through the induction of Beclin-1 and PERK26,36–38.  
 The anti-cancer activity of MDA-7/IL-24 involves more than apoptosis and autophagy. 
Another hallmark of cancer is invasion and metastasis to distant sites. MDA-7/IL-24 can prevent 
both processes through the downregulation of focal adhesion kinase (FAK) and matrix 
metalloproteinases (MMPs), as well as proteins such as TGF-β, CD44, and upregulation of E-
cadherin39–41. In total, these gene regulated by MDA-7/IL-24 lead to effective inhibition of 
metastasis. Beyond these functions, MDA-7/IL-24 also blocks angiogenesis, the formation of 
new blood vessels42,43. Vascular endothelial growth factor, basic fibroblast growth factor, and 
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PI3K/Akt signaling are all downregulated by MDA-7/IL-24, which inhibits angiogenesis and 
starves the tumor of oxygen and essential nutrients26,37,44.  
 The major benefit of MDA-7/IL-24 is that it is effective against a wide-variety of cancers 
regardless of anatomic origin or p53 status45. MDA-7/IL-24 spares normal cells from its killing 
effects, making MDA-7/IL-24 an ideal treatment for cancer. As such, MDA-7/IL-24 has already 
entered the clinic for a phase I clinical trial. Repeat intratumoral injections of MDA-7/IL-24 were 
found to be well-tolerated and 44% of lesions demonstrated induction of apoptosis in local and 
distant sites. One patient demonstrated complete regression of the tumor and was still alive 
>600 days after the treatment46,47,20.  
 Finally, treatment for prostate cancer is currently to be limited to surgery, 
chemotherapy, and hormone therapy. MDA-7/IL-24 has been found to be effective against 
prostate cancer in vitro and in vivo. In vitro, MDA-7/IL-24 induces apoptosis marked by caspase 
3 cleavage and an inhibition of cellular proliferation48. In orthotopic and transgenic mouse 
models, MDA-7/IL-24 is effective at inducing regression of primary tumors and 
prevention/treatment of metastases49–51. Even if MDA-7/IL-24 alone is not enough to induce 
complete regression, it can be used in conjunction with other pharmacological agents such as 
Sabutoclax or other BH3 mimetics to enhance cancer cell-killing52,53.  
  MDA-7/IL-24 plays a role in stimulation of the immune system as another method of 
anticancer activity30. A study in human PBMCs found MDA7/IL-24 could upregulate 
proinflammatory proteins such as IFNγ, IL-6, IL-1β, and GM-CSF, TNF-α54. Upregulation of these 
proteins can induce cancer cell death through the activation of cytotoxic T-cells55, JAK/STAT 
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signaling to induce apoptosis56, and sensitization to chemotherapeutics57.  For this study, 
signaling pathways involved in T-cell activation are the most intriguing. 
miRNAs 
 miRNAs are small noncoding RNAs that are about 22 nucleotides long58. They function 
as post-transcriptional gene silencers through degradation of mRNA or inhibition of 
translation58. lin-4 and let-7 were the first miRNAs discovered in Caenorhabditis elegans and 
were found to regulate the timing of larva development59. Since the initial discovery, it has 
come to light that miRNAs are evolutionarily conserved regulators of gene expression. Humans, 
zebrafish, mice, fruit flies, worms, and even plants encode and make use of miRNAs60–62.  
 miRNAs function to silence gene expression by targeting the 3’ untranslated region 
(UTR) in the mRNA of a target gene58. In some cases, miRNAs can bind to 5’ UTRs as well59. 
miRNAs bind to 2-8 nucleotide sequences which are complementary to the miRNA sequence59. 
miRNAs that bind perfectly to this sequence trigger mRNA degradation while miRNAs that bind 
imperfectly inhibit translation59.  In mammalian cells, the inhibition of translation is the 
predominant mechanism of gene silencing as perfect matches between miRNAs and mRNAs are 
rare. In animal models, it is estimated that miRNAs can target up to 60% of protein-coding 
mRNAs and single miRNAs can potentially have more than one hundred targets61,63.  
 There are two pathways from which miRNAs are generated: the canonical and non-
canonical pathways64. In both cases, miRNAs are transcribed by RNA polymerase II from the 
coding gene. This produces the primary-miRNA (pri-miRNA) which is an mRNA complex which 
contains a hairpin loop structure. In the canonical pathway, the hairpin is cleaved into the 
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precursor miRNA (pre-miRNA) by the Drosha-DGCR8 complex65,66. In the non-canonical 
pathway, the pri-miRNA is cleaved by the spliceosome64.  From there the pathways converge 
and follow the same route. The pre-miRNA hairpin structure is exported into the cytoplasm by 
Exportin-567. The pre-miRNA is then cleaved by DICER into two mature single-stranded miRNAs 
which are referred to as -5p or -3p. While the mature miRNAs came from the same encoding 
gene, the -5p and -3p variants have complementary sequences and thus will target different 
mRNAs68. The single-stranded mature miRNA is loaded into the RNA-induced silencing complex 
which contains AGO2 and TRBP68. These proteins guide the miRNA to the gene target and 
suppress gene expression through translation inhibition or mRNA degradation61–63,69.  
 Drosha, DICER, and DGCR8 are the primary regulators of miRNA processing, but miRNA 
expression can be affected a number of ways. miRNA expression can be regulated at the 
transcriptional level through transcription factors. C-MYC, E2F1, and p53 are important 
transcription factors that have roles in cell growth/death, genome stability, and cancer 
progression61,70,71. These three transcription factors also directly regulate a number of miRNAs. 
Upregulation of these transcription factors leads to aberrant miRNA expression. miRNA 
expression is affected by mutations in the genes by which they are encoded72. If there is loss of 
the miRNA gene, it will not be transcribed leading to absence of gene silencing. On the opposite 
end of the spectrum, if there is amplification of the gene, the miRNA may also be transcribed in 
greater levels leading to enhanced gene silencing73. Chromosomal abnormalities can often 
result in the gain or loss of miRNA expression as well63,74,75.  
Like any other gene, miRNAs can be regulated through epigenetics76. Hypermethylation 
of CpG islands in the promoters of miRNA genes can inhibit miRNA expression76. Meanwhile, 
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hypomethylation in the promoter can result in an increase of miRNA expression. In addition, 
histone modifications can enhance or inhibit transcription of miRNAs76. These miRNAs are 
subject to epigenetic regulation, but can also regulate the epigenetic machinery, adding 
another layer of gene regulation to miRNAs77,78. They can influence global DNA methylation by 
targeting DNA methyltransferases and tet methylcytosine dioxygenases as well as histone 
modifications through targeting genes for proteins such as HDAC179,80,81. 
In cancer, miRNAs have conflicting and sometimes complicated roles82. To begin, miRNA 
expression is often dysregulated due to increased expression of oncogenic transcription factors, 
or loss of expression of tumor suppressing transcription factors83. Amplification of oncogenes 
and loss of tumor suppressors can result in disruption of normal miRNA processing or 
transcription. Within the field of cancer, miRNAs can fall into two categories: oncomiRs or 
tumor-suppressor miRNAs61,63,69.  
As the name suggests, oncomiRs function to promote oncogenesis through inhibiting 
tumor suppressor genes84,85. These miRNAs are generally upregulated in cancers. One such 
oncomiRs is miR-221 which functions to suppress cell cycle arrest, apoptosis, and toxic 
autophagy and promote tumor progression86,87. It is frequently upregulated in a number of 
cancers including prostate88. MDA-7/IL-24 downregulates this miRNA and induces cancer cell 
death and when this miRNA is forcibly overexpressed in combination with MDA-7/IL-24, it can 
prevent cell death89. This shows how potent just one oncomiR can be in the protection and 
progression of cancer cells.  
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On the other side of the spectrum, tumor suppressor miRNAs work to silence 
oncogenes, anti-differentiation, and/or anti-apoptosis genes90–92. The expression of these 
miRNAs can be lost in cancer resulting in increased cell growth and evasion of apoptosis. Let-7 
is an example of a tumor suppressor miRNA which targets Ras93. When let-7 is overexpressed in 
cancer cells there is a reduction of cell growth through suppression of RAS as well as other 
oncogenes and cell-cycle associated genes94–96. This effect has been seen in vitro as well as in 
vivo and the enormous potential of let-7 as a tumor suppressing miRNA is still being explored 
today61,63,69. 
Their prevalent role in cancer makes miRNAs interesting targets for the treatment of the 
disease. In order to inhibit the activity of miRNAs, researchers have used a number of 
strategies97. The first is a miRNA sponge which is a synthetic mRNA which acts as a decoy for 
miRNAs98. It is homologous to a target mRNA and contains the target sequence to which the 
miRNA will bind. This prevents gene silencing of the true mRNA. This technique is easy to use in 
vitro, but in vivo it is limited to transgenic animals which express the sponge in specific 
tissues69,99,100. Anti-miRNA oligonucleotides (AMOs) are another popular technique for 
inhibiting miRNA function101. AMOs have high complementarity with miRNAs and tightly bind 
them so they cannot bind with the mRNA target102. However, AMOs have to be chemically 
modified in order to prevent degradation by exonucleases before they can be used in vivo. One 
example is locked nucleic acids (LNA) which are RNA analogs which are locked in an RNA-
mimicking conformation by an extra bridge between the 2’ carbon and 4’ oxygen101. These LNAs 
are thermally stable upon binding with miRNAs, aqueously soluble, compatible with RNase H 
cleavage, and have low toxicity. They are also resistant to nuclease activity which makes their 
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use possible for in vivo applications62,69. However, despite their increased activity AMOs and 
LNAs require a method of delivery in vivo. Some delivery methods include conjugation with 
cholesterol, liposome-mediated delivery, nanoparticle delivery, and antibody-based 
delivery103,104. Careful selection of a delivery route, and method of inhibition is extremely 
important as inhibition of an off-target miRNA could potentially lead to deleterious effects69,105.  
miRNAs in Prostate Cancer 
 miRNAs can potentially serve as biomarkers to assess prostate cancer risk and 
progression106. PSA, which was frequently used for disease diagnosis, is subject to variability 
because of infections or inflammation107. Therefore, there is a poor correlation between PSA 
levels and disease aggressiveness108,109. Tumor grade and clinical stage can also be taken into 
account, but they also have limitations in predicting metastasis and disease progression110,111. 
 miRNA profiling of prostate cancer tissues has been used to identify a number of 
miRNAs that appear to be associated with disease progression. For instance, let-7f, miR-19b, 
and miR-184 are associated with advanced disease112. miR-101, miR-200a, and miR-200b are 
differentially expressed in the localized tumors versus a tumor which has metastasized113. This 
indicates these miRNAs could be biomarkers for the formation of lethal metastases. In some 
studies, circulating miRNAs were observed in the serum of prostate cancer patients114,115. These 
miRNAs include: miR-141, miR-26, miR-195, miR-30c. Some of these circulating miRNAs were 
found to be inversely associated with the Gleason score of the tumor110,111. However, using 
serum miRNAs as biomarkers remains controversial due to a lack of relevant data and 
conflicting results in serum compared to tissues111. miRNAs could even serve as a biomarker for 
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androgen sensitivity which can lead to difficult-to-treat tumors116. Androgen receptors are 
under control of miR-130, miR-203, and miR-205 which are expressed at low levels in prostate 
cancer. miR-34a and miR-34c have an inverse correlation with androgen receptor 
expression117,118. Monitoring these miRNAs can also enable clinicians to better determine how 
long to continue ADT as treatment for mCRPC.  
 In this study, we seek to identify miRNAs regulated by MDA-7/IL-24 which may play a 
role in specifically regulating anti-cancer activity. 
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Materials and Methods 
 
Cell Lines  
 RWPE-1, DU145, PC3, and PC3-ML were purchased from American Type Culture Collection 
(Manassas, VA). RWPE-1 was maintained in Keratinocyte serum-free media with provided supplements 
and 1% penicillin and streptomycin. DU145 was maintained in Eagle’s Minimum Essential Media (EMEM) 
with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin. PC3 was maintained in F-12K 
media with 10% FBS and 1% penicillin and streptomycin. PC3ML was maintained in Dulbecco’s Modified 
Eagle Media (DMEM) with 10% FBS and 1% penicillin and streptomycin. Cells were recovered from liquid 
nitrogen stock provided by Praveen Bhoopathi and Anjan Pradhan which were frozen at passage 2 and 
were not used beyond passage 9. Cells were maintained at 37°C in 5% CO2 humified incubators. Cells 
were maintained in T-75 flasks (Thermofisher) at 50-60% confluency. For downstream experiments, cells 
were seeded in 6 cm dishes at 60% confluency. RWPE-1 was used as the control cell line for all 
experiments. 
Viral Infection 
 For the plate array, Ad.5-CMV-mda-7 and Ad.5-null were used to treat cells for the PCR plate 
arrays. For all other experiments, Ad.5/3-CMV-mda-7 was used to transduce MDA-7/IL-24 following viral 
infection and Ad.5/3-null was used as a control. Ad.5/3 vector was used to control for low infectibility of 
PC3 by Ad.5 adenovirus. Cells were treated with 2000 vp/cell in serum-free DMEM media for 4 hours. 
This dose was chosen because it is sublethal. After 4 hours, complete media was added to the plates. 72 
hours after infection, cells were collected for experiments. 
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miRNA and total RNA isolation  
 miRNA and total RNA was isolated using the miRNeasy kit purchased from Qiagen (Hilden, 
Germany). Cells were lysed directly in the 6 cm dish with 700 µL QIAzol lysis reagent and homogenized 
by shaking for 5 minutes. The QIAzol was collected from the plate and transferred to a 1.5 μL centrifuge 
tube. 140 µL chloroform was added and the tube was vortexed for 20 seconds. The tube was centrifuged 
15,000 rpm for 15 minutes at 4°C. The upper aqueous phase was transferred to a new 1.5 μL centrifuge 
tube and 1.5 volumes of 100% ethanol was added to precipitate the RNA. The solution was transferred 
to an RNeasy Mini column and centrifuged at >8,000xg for 15 seconds. The flow-through was discarded. 
700 µL RWT was added to the column and centrifuged at >8,000xg for 15 seconds. The flow-through was 
discarded. 500 μL RPE was added to the column and centrifuged at >8,000xg for 15 seconds. This step 
was repeated but the column was centrifuged at >8,000xg for 2 minutes. The membrane was dried by 
centrifuging at 15,000 rpm. 30 µL of RNase free water was added directly to the membrane and then 
centrifuged at 15,000 rpm for 15 seconds. The concentration of RNA was measured using the nanodrop. 
RNA was stored at -80°C.  
miRNA inhibition and overexpression 
 miExpress™ expression vector and miArrest™ inhibitor against miR-125a-5p were purchased 
from Genecopoeia (Rockville, MD). Cells were transfected in serum free media with respective vectors 
using the FuGene(6) transfection reagent purchased from Promega (Madison, WI). Cells were incubated 
with the transfection reagents and vectors for 4 hours. After 4 hours complete media was added. 72 
hours later positive transfection was observed by expression of GFP and mCherry, respectively. Pure 
populations of transfected cells were isolated by fluorescent-activated cell sorting in the Flow Cytometry 
Core lab by gating for cells strongly expressing the reporter. miRNA and total RNA expression were 
collected from these populations for further analysis.  
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qRT-PCR 
 Gene and miRNA specific TaqMan primers were purchased from Thermofisher (Waltham, MA). 2 
μg RNA was reverse transcribed into cDNA using the High-Capacity cDNA Reverse Transcription Kit 
purchased from Thermofisher. For miRNAs, cDNA was generated using the miRNA specific primers 
supplied with the TaqMan primers. For gene targets, cDNA was generated with random primers 
supplied in the kit. cDNA synthesis was performed using the thermocycler and the following conditions: 
25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes, and then hold at 4°C. If not used 
immediately for downstream applications, cDNA was stored at -20°C for up to one week. q-RT-PCR was 
performed using TaqMan Master Mix, cDNA, and RNase free water for a final volume of 20 μL. The 
parameters for the thermocycler are as follows: 50°C for 2 minutes, 95°C for 10 minutes, then 95°C for 
15 second and 60°C for 1 minute repeated for 40 cycles. qRT-PCR experiments were done in triplicate 
and repeated at least three times.  
miRNA Plate Array - Prostate Cancer 
 miScript miRNA PCR Plate Array specifically for prostate cancer (Catalog #: MIHS-112Z) was 
purchased from Qiagen. The miScript II RT Kit purchased from Qiagen was used for reverse transcription. 
cDNA was synthesized using 2 µg of RNA template, the miScript HiSpec buffer and oligo-dT primers for 
amplification of mature miRNAs. The reaction mix was incubated at 37°C for 1 hour and then 95°C for 5 
minutes. Immediately after cDNA synthesis, we proceeded with the PCR plate array. The total 20 µL 
cDNA mix was diluted in 200 µL of RNAse-free water for a final concentration of 10-20 ng of cDNA per 
well. The miScript SYBR Green PCR Kit purchased from Qiagen was used to prepare the master mix for 
the RT-PCR reactions containing cDNA (10-20 ng per well), QuantiTect SYBR green Master mix, and 
miScript Universal Reverse Primer. The plate was centrifuged before adding the PCR master mix to 
ensure the probes were at the bottom of the wells. 25 µL of the master mix was added to each well in 
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the PCR array plate using a multichannel pipettor. Results were analyzed using Qiagen’s GeneGlobe Data 
Analysis Center. The PCR plate arrays were not repeated.  
Statistical Analysis 
 Statistical analysis was done by t-test for two samples and ANOVA for more than two samples in 
GraphPad Prism. P-values less than .05 were considered to be statistically significant.  
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Results 
miRNAs are regulated by MDA-7/IL-24 in prostate cancer cell line 
 The miScript PCR plate array contained probes for 84 miRNAs that are found to be differentially 
regulated in prostate cancer. miRNAs let-7c and 34c were differentially regulated in RWPE-1, an 
immortalized normal prostate epithelial cell line, after treatment with Ad.5-mda-7 (Fig. 1A). In DU145, a 
prostate cancer cell line, eight miRNAs were downregulated: 125a, 145, 146b, 183, 23b, 27b, 330, 455. 
Four miRNAs were upregulated: 20b, 494, 616, 7-5p (Fig. 1B). In comparing the effect of MDA-7/IL-24 
between DU145 and RWPE-1, more miRNAs were regulated in DU145 than RWPE-1 (Fig. 1C).  
Validation of PCR plate array 
 Two miRNAs were selected to independently validate the results of the PCR plate array based on 
an interest in their predicted gene targets which included the Wnt signaling pathway and genes related 
to DNA damage. miR-330 was significantly downregulated in DU145 after Ad.5-mda-7 treatment for 72 
hours (Fig. 2A). This miRNA is upregulated in DU145, PC3, and PC3ML prostate cancer cell lines 
compared to RWPE-1 (Fig.2B) miR-183 is significantly downregulated after treatment with Ad.5-mda-7 
(Fig. 2C). miR-183 is also upregulated in the three prostate cancer cells lines compared to RWPE-1 (Fig. 
2D).  
miR-330 and miR-183 changes are specific to DU145 
 To confirm that these miRNAs are relevant to the prostate cancer context, their expression was 
evaluated in PC3 and PC3ML. Cells were treated with 2000 vp/cell dose of Ad.5/3-mda-7 to control for 
low expression of CAR receptors on PC3. This ensures the cells are being equally infected. miR-330 (Fig. 
3A) and miR-183 (Fig. 3B) were significantly downregulated in DU145 and were not downregulated by 
MDA-7/IL-24 in PC3 and PC3ML. 
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Three miRNAs were downregulated in three prostate cancer cell lines  
There were 10 other miRNAs to choose from that were regulated in DU145. We evaluated all 
ten and found 3 which were consistently downregulated in all three prostate cancer cell lines. miR-125a 
(Fig 4A), miR-145 (Fig 4B), and miR-23b (Fig. 4C) were significantly downregulated after treatment with 
Ad.5/3-mda-7 for 72 hours. TargetScan (Release 7.2) was used to identify potential gene targets of these 
miRNAs. NOD-Like receptor family caspase recruitment domain containing 5 (NLRC5) was predicted to 
be a target of miR-125a and would be a novel target of MDA-7/IL-24.  After 72 hours treatment with 
Ad.5/3-mda-7, it was significantly upregulated in prostate cancer cell lines DU145 and PC3 while its 
expression was unchanged in RWPE-1 (Fig. 5A). KLF4 is a predicted target of miR-145. This gene was 
significantly upregulated in DU145, but not PC3 and RWPE-1 (Fig. 5B). KLF15 is another potentially novel 
target of MDA-7/IL-24 predicted by TargetScan.  It was significantly upregulated in both prostate cancer 
cell lines, but not RWPE-1 (Fig 5C). 
Regulation of NLRC5 by miR-125a 
 NLRC5 is an interesting gene target because it has not been studied with regards to MDA-7/IL-24 
and it may play a role in immune evasion. To evaluate if miR-125a is regulates NLRC5 expression, we 
used the miArrest™ plasmid to inhibit miR-125a expression. After inhibition, NLRC5 expression was 
significantly increased (Fig. 6A). To determine if the opposite is true, we used the miExpress™ plasmid to 
induce miR-125a expression. While miR-125a was significantly upregulated, NLRC5 expression did not 
change (Fig. 6B). This indicates that miR-125a expression alone may not be sufficient to downregulate 
NLRC5. This is likely due to NLRC5 already being expressed at very low levels or not expressed at all in 
prostate cancer cell lines. As such, miR-125a cannot drive down the expression any lower. 
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MDA-7/IL-24 regulates miR-125a expression through DICER. 
 Finally, to determine how miR-125a is regulated by MDA-7/IL-24 we looked at the expression of 
miR-125a precursors and the expression of miRNA processing enzymes. 72 hours after treatment, there 
is no change to the precursor miRNA in DU145 or PC3, indicating that miRNA expression is regulated 
after export to the cytoplasm (Fig. 7A). In these cell lines, treatment with Ad.5/3-mda-7 for 72 hours 
resulted in the downregulation of DICER, a key enzyme for processing miRNAs into their mature and 
active forms (Fig 7B). Lastly, a DU145 cell line which stably overexpressed DICER was treated with 
Ad.5/3-mda-7. There was no change in miR-125a expression which indicates miR-125a is regulated by 
MDA-7/IL-24 through DICER. 
 
 
 
 
 
 
 
 
 
 
 
19 
 
Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RWPE-1 - Ad.5-null vs. Ad.5-mda-7 
DU145 - Ad.5-null vs. Ad.5-mda-7 
1A
A 
1B 
20 
 
 
 
Figure 1. miScript PCR Plate Array. (A) RWPE-1 were treated with 2000 vp/cell dose of Ad.5-null or Ad.5-
mda-7 for 72 hours. miRNAs highlighted in blue are greater than 2-fold upregulated. miRNAs highlighted 
in yellow are greater than 2-fold downregulated. (B) DU145 were treated with 2000 vp/cell dose of 
Ad.5-null or Ad.5-mda-7 for 72 hours. miRNAs highlighted in blue are greater than 2-fold upregulated. 
miRNAs highlighted in yellow are greater than 2-fold downregulated. (C) Comparison of miRNAs 
differentially regulated in DU145 compared to RWPE-1 after MDA-7/IL-24 treatment.  
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Figure 2. Validation of PCR plate array. (A) miR-330 expression in DU145 after treatment with 2000 
vp/cell dose of Ad.5-null or Ad.5-mda-7 for 72 hours. (B) Basal expression of miR-330 in three prostate 
cancer cell lines compared to RWPE-1. (C) miR-183 expression in DU145 after treatment with 2000 
vp/cell dose of Ad.5-null or Ad.5-mda-7 for 72 hours. (D) Basal expression of miR-183 in three prostate 
cancer cell lines compared to RWPE-1. * denotes p<0.05. Each experiment was repeated three times. 
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Figure 3. miR-330 and miR-183 changes are specific to DU145. (A) miR-330 expression in DU145, PC3, 
and PC3ML 72 hours after treatment with 2000 vp/cell dose of Ad.5/3-mda-7 (B) miR-183 expression in 
DU145, PC3, and PC3ML 72 hours after treatment with 2000 vp/cell dose of Ad.5-mda-7. * denotes 
p<0.05. Each experiment was repeated three times. 
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Figure 4. Three miRNAs were downregulated in three prostate cancer cell lines. (A) miR-125a (B) miR-
145 (C) miR-23b expression after treatment with 2000 vp/cell dose of Ad.5/3-null or Ad.5/3-mda-7 for 
72 hours. * denotes p<0.05. Each experiment was repeated three times. 
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Figure 5. Gene targets of miR-125a, miR-145, and miR-23b respectively. (A) NLRC5 (B) KLF4 (C) KLF15 
expression after treatment with 2000 vp/cell dose of Ad.5/3-null or Ad.5/3-mda-7 for 72 hours. * 
denotes p<0.05. Each experiment was repeated three times. 
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Figure 6. Regulation of NLRC5 expression by miR-125a. (A) miR-125a was inhibited by transfection with 
miR-125a miArrest plasmid in DU145 and PC3. Control cells were treated with scramble control plasmid. 
Cells were treated for 72 hours. (B) mir-125a was overexpressed by transfection with miR-125a 
miExpress plasmid in DU145 and PC3. Controls were treated with scramble control plasmid. Cells were 
treated for 72 hours. * denotes p<0.05. Each experiment was repeated three times.  
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Figure 7. MDA-7/IL-24 regulates miR-125a expression through DICER. (A) Expression of the precursor 
RNA for miR-125a product prior to exportation to the cytoplasm after treatment with 2000 vp/cell dose 
of Ad.5/3-null or Ad.5/3-mda-7 for 72 hours. (B) Expression of miRNA processing enzyme DICER after 
treatment with 2000 vp/cell dose of Ad.5/3-null or Ad.5/3-mda-7 for 72 hours. (C) Expression of miR-
125a in a DICER-stable DU145 cell line. * denotes p<0.05. Each experiment was repeated three times. 
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Discussion 
The current study and a recent study by Pradhan et al. indicate that MDA-7/IL-24 regulates 
miRNA expression through the processing enzyme DICER. Downregulation of DICER leads to global 
dysregulation of all miRNAs that are processed through this enzyme. Upregulation of DICER can confer 
resistance to the anticancer effects of MDA-7/IL-24. This provides strong evidence that miRNAs play a 
role in the anti-cancer activity of MDA-7/IL-24. The reason for MDA-7/IL-24’s cancer-specificity is still 
unknown and miRNAs may be the key to determining the mechanism. Here, we focused on miRNAs that 
were only regulated in cancer cells, but remained unchanged in the normal cell line. It is most likely 
these types of miRNAs that play a role in cancer-specificity. However, miRNAs that are regulated in the 
normal cell type may also be interesting targets. miRNAs could potentially confer susceptibility or 
resistance to MDA-7/IL-24 depending on their gene targets. For instance, in addition to upregulation of 
DICER, it has been previously reported that blocking the p38 MAPK pathway pharmacologically can 
protect cancer cells from MDA-7/IL-24-mediated apoptosis119. In future studies, we hope to explore and 
determine which miRNAs can make cancer cells resistant to MDA-7/IL-24 and/or identify miRNAs that 
can make normal cells susceptible to MDA-7/IL-24 treatment. Identifying such miRNAs could enhance 
the efficacy of MDA-7/IL-24 through combination treatments. MDA-7/IL-24 is a potent anticancer 
agent20,26,37 and a combination treatment with miRNAs could give hope of a cure for many types of 
cancer including those that are difficult to treat. 
 miRNAs regulated by MDA-7/IL-24 were studied to determine if they were regulated across 
multiple cell lines. Some miRNAs, such as miR-183 and miR-330, appeared to be only regulated by MDA-
7/IL-24 in one cell line, but not the others. This is likely due to differences in the genetic backgrounds 
across these cell lines. Going forward, miR-125a was downregulated by MDA-7/IL-24 across all the 
prostate cancer cell lines and was unchanged in normal prostate cell lines. A known target of miR-125a 
is BAK, a proapoptotic protein which is regulated by MDA-7/IL-24 which indicated that this could be a 
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miRNA that is relevant to the anticancer effects of MDA-7/IL-24 26,120. The role of miR-125a in cancer is 
somewhat controversial. Several reports indicate it acts as a tumor suppressor with expression being 
lost in cancers such as breast121, ovarian122, hepatocellular carcinoma123, colon124, and cervical125. 
Meanwhile, other reports indicate that it can act as an oncomiR in cancers such as pancreatic126. In the 
case of prostate cancer, the miR-125 family which includes miR-125b have been found to act as 
oncomiRs126. One study by Yi Fu and Fuhua Cao found that miR-125a, is specifically upregulated in 
prostate cancer cell lines and downregulating it has anti-proliferative effects127. With minimal 
information available on the role of miR-125a in prostate cancer and its known target being BAK, we 
chose to explore novel gene targets of this miRNA which might be relevant to the cancer-specificity of 
MDA-7/IL-24. 
miR-125a has also been found to play a role in regulation of the immune system128,129. It works 
in combination with two other miRNAs to regulate toll-like receptor (TLR) signaling. TLR signaling plays a 
vital role in balancing the scales between pro-inflammatory and anti-inflammatory cascades which are 
triggered by pathogens130. In this context, miR-125a is upregulated by interleukin 10 (IL-10) which acts as 
an inhibitor of TLR signaling and also targeted genes associated with inflammation. As a result, the 
cluster of miRNAs including miR-125a act as inhibitors of the TLR signaling pathway131. TLR signaling 
plays a role in the activation of macrophages as well. Macrophage activation falls into two categories: 
classical and alternative. Macrophages activated by ligands such as lipopolysaccharide (LPS) of IFNγ are 
considered classically activated while macrophages activated by cytokines such as IL-10, IL-4, and IL-13 
are alternatively activated132–134. One study found that miR-125a suppressed the classical activation and 
enhanced alternative activation which falls in line with the regulation of miR-125a by IL-10129. Another 
study found that miR-125a in combination with miR-125b can activate NF-κB signaling by suppressing its 
negative regulator TNFAIP3135. Constitutive NF-κB signaling is reported to promote tumor initiation, 
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metastasis, and angiogenesis by inducing chronic inflammation in the tumor microenvironment136. This 
suggests that miR-125a may be a potential oncomiR with the ability to shape the immune responses. 
In this study, NLRC5 was predicted by TargetScan to be a target of miR-125a. NLRC5 belongs to a 
family of leucine-rich containing proteins which function as pattern-recognition receptors (PRRs)137. 
PRRs play a role in innate and adaptive immunity by sensing microbe-associated patterns and danger-
associated molecular patterns137. Not all NLRs function as PRRs and in fact, they can fall into one of three 
categories: PRRs which sense microbes and activate transcriptional changes in the host, inducers of the 
formation of the inflammasome which triggers cell death, or nuclear-translocators that act as 
transcription transactivators138. NLRC5, sometimes referred to as class I transactivator (CITA), falls into 
the class of transcriptional activators139. NLRC5’s primary function is to transcriptionally activate major 
histocompatibility complex (MHC) class I genes139. NLRC5 shares this function with class II transactivator 
(CIITA) which can also activate MHC class II genes140. MHC class I and II genes play a role in immune 
evasion which is another hallmark of cancer35,141. MHC class I genes present peptides derived from the 
cytosol to CD8+ cytotoxic T-cells142. MHC class II genes present vesicular-derived peptides to CD4+ 
helper T-cells143. Loss of expression of the MHC class I genes has been seen in a variety of cancers 
including breast, pancreatic, cervical, and non-small cell lung cancer. Researchers found that inducing 
expression of MHC class I and class II genes induces tumor rejection and induced a vaccine effect against 
new MHC-negative cancer cells144–146. Regulation of NLRC5 could be a new mechanism for MDA-7/IL-24 
to stimulate the immune system. By restoring, NLRC5 and MHCI expression to cancerous cells, cytotoxic 
T-cells could now target them for destruction. This could enhance the efficacy of MDA-7/IL-24 
treatment. 
The down-regulation of miR-145 by MDA-7/IL-24 is a conflicting result which is both expected 
and unexpected. miR-145 is well established in the literature to act as a tumor suppressor. Loss of miR-
145 expression has been reported in multiple cancers including prostate111,147–150. Its expression inhibits 
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invasion and metastasis by regulating proteins such as cadherins, fibronectin, and SMAD3151. One could 
envision MDA-7/IL-24 upregulating this miRNA to enhance cancer cell-killing and prevent metastasis. 
However, it is likely that MDA-7/IL-24 is downregulating miR-145 because this miRNA is dependent on 
DICER for processing. Although it is downregulated in this study, it is still possible for miR-145 to 
contribute to cancer cell-killing by MDA-7/IL-24 because some of its predicted targets include tumor 
suppressors. Expression of these tumor suppressors would be upregulated after miR-145 inhibition.  
miR-23b is another miRNA that has contrasting roles in different cancers. In bladder152 and 
cervical153 cancer it has been reported to function as a tumor suppressor. This miRNA inhibits cellular 
proliferation by targeting the PI3K-AKT pathway and inhibits epithelial-mesenchymal transition (EMT) by 
targeting cytoskeletal remodeling genes154. In glioma155 and renal156 cancer, miR-23b is upregulated and 
acts as an oncomiR. The most unfavorable consequence of miR-23b oncomiR function is the 
downregulation of PTEN which in turn, promotes cancer cell proliferation157. Its function is further 
complicated in breast and prostate cancer where it has been reported to act as both a tumor-suppressor 
and an oncomiR158–161. Interestingly, miR-23b is also reported to play a role in the production of ROS 
which is a mechanism by which MDA-7/IL-24 mediates cell killing4. In the context of miR-23b, inhibition 
results in the generation of reactive oxygen species through the upregulation of NOX4 which is a 
member of the NADPH oxidase family. Inhibition also increases proline oxidase expression to generate 
ROS162. Taken together, we categorized miR-23b as an oncomiR in this study and focused on potential 
new gene targets that function as tumor suppressors after MDA-7/IL-24 treatment.  
 Krüppel-like factor 4 and 15 (KLF4 and KLF15) emerged as targets of the miR-145 and miR-23b, 
respectively. Both were found to be upregulated by MDA-7/IL-24 treatment. These genes belong to a 
family of transcription factors which contain zinc-finger domains in the C-terminal which target DNA 
with GC-rich sequences, preferably a 5’-CACCC-3’ motif163. These transcription factors are unique 
because they contain three Cysteine2/Histidine2 containing zinc fingers located at the extreme C-
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terminus, share a highly conserved seven residue sequence between zinc fingers, and can also bind to 
the GT box164–166. KLF4 has been extensively studied in cancer, while KLF15 is a newcomer to the field. 
 KLF4, also known as gut enriched Krüppel-like factor, is well-known for its role in self-renewal 
and pluripotency in embryonic stem cells, hematopoietic cells, and bone marrow stromal cells through 
activation of genes which maintain these processes such as NANOG, OCT4, and SOX2167. In cancer, KLF4 
has conflicting roles as an oncogene and as a tumor suppressor. For instance, in triple-negative breast 
cancer KLF4 has been found to be upregulated and silencing it inhibits cell migration and viability168. 
Some studies draws a connection between miR-145 and KLF4 in bladder cancer169,79. miR-145 is 
downregulated and KLF4 is upregulated in bladder cancer cells. Restoration of miR-145 drove KLF4 
expression down and induced apoptosis by downregulating aerobic glycolysis170. However, there is 
substantial evidence that supports KLF4’s function as a tumor suppressor. In pancreatic171, colorectal172, 
and prostate cancer173, KLF4 expression is downregulated in cell lines and patient samples. Notably, in 
prostate cancer, restoration of KLF4 inhibited cell proliferation, migration, and induced cell cycle 
arrest174. Here, MDA-7/IL-24 upregulated KLF4 while downregulating miR-145. Considering the 
literature, miR-145 inhibition would have oncogenic effects. Even though miR-145 is inhibited in this 
context, MDA-7/IL-24 is still capable of killing cancer cells. miR-145 inhibition would allow for the 
upregulation of KLF4 and thus enable its tumor-suppressing actions. Combined with the anti-cancer 
function of MDA-7/IL-24, this observation suggests that miR-145 inhibition is not sufficient to induce 
tumorigenesis. It is also possible that miR-145 is not directly targeting KLF4 as a number of miRNAs have 
been reported to act on this gene.  
KLF15, also known as kidney-enriched Krüppel-like factor (KKLF), is among one of the KLFs which 
has yet to have its protein interaction domains characterized. It is expressed in metabolically active 
endothelial cells found in liver, kidney, and heart tissue163,175. KLF15 has established itself as a regulator 
of insulin-sensitivity, glucose uptake176, and lipid metabolism177. In disease, KLF15 has also been 
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implicated in kidney disease as the loss of KLF15 is associated with podocyte differentiation and renal 
fibrosis175. It functions to suppress cardiac hypertrophy as well178. Studies in KLF15 knockout mice found 
increased blood pressure, increased cardiac mass, and dysfunction of the left ventricle179. In studies of 
heart failure in humans, KLF15 mRNA is down-regulated in left ventricle tissue178. In recent years, KLF15 
has emerged as a potential novel tumor suppressor. Studies in breast, lung, and gastric cancer models 
found KLF15 expression is downregulated in cancer tissue compared to normal tissue. Overexpression of 
KLF15 suppressed proliferation of cancer cells by upregulating p21 and p27 which induce cell cycle 
arrest180–182. MDA-7/IL-24 has previously been shown to induce p27 expression183 and here, KLF15 
expression. KLF15 was not upregulated in normal cells and this may indicate a potential mechanism to 
explain cancer-specific killing by MDA-7/IL-24. Here, we did not go in depth to explore the connection 
between KLF15 and MDA-7/IL-24. Further studies would include blocking KLF15 expression in 
combination with MDA-7/IL-24 treatment to determine if p27 expression can be inhibited to save cancer 
cells from cell-cycle arrest.  
While pondering how miRNAs play a role in MDA-7/IL-24 efficacy, there was also a question that 
lingered in the back of our minds: what makes normal cells normal? Inevitably, the question ended up 
being far outside of the scope of this study. Fortunately, there is an ever-growing breadth of knowledge 
that seeks to determine what truly differentiates cancer and normal cells. miRNAs have firmly 
established their place as regulators of gene expression so it is not far-fetched to believe that miRNAs 
may play a role in maintenance of normal physiology. The best way to discern which miRNAs contribute 
to a normal phenotype would be through RNAseq. This would allow researchers to identify known and 
new miRNAs. The goal would be to identify miRNAs that are only expressed in normal cells, but not in 
any type of cancer cells. Alternatively, we could also identify miRNAs which are never expressed in 
normal cells. It is not likely that one miRNA is what decides if a cell is normal so a strategy using RNAseq 
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would give us numerous potential miRNAs. From there, overexpression or inhibition experiments could 
be done to determine if groups of miRNAs can transform a cancer cell into a “normal” cell or vice versa.  
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